Spots Global Cancer Trial Database for hematopoiesis
Every month we try and update this database with for hematopoiesis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) | NCT00961064 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
Screening for Hematology Branch Protocols | NCT00001620 | Hematologic Dis... Donors Healthy Volunte... | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome | NCT00217594 | Myelodysplastic... | Alemtuzumab (Ca... | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
Screening for Hematology Branch Protocols | NCT00001620 | Hematologic Dis... Donors Healthy Volunte... | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
Evaluation, Treatment, and Training for Patients With Blood Disorders | NCT00001397 | Hematologic Dis... | 2 Years - 110 Years | National Institutes of Health Clinical Center (CC) | ||
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) | NCT00961064 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) |